Dexcom (NSDQ:DXCM) touted data today showing that people with Type II diabetes who are using multiple daily injections of insulin can benefit from the use of continuous glucose monitoring.
Those in the 158-patient study using Dexcom’s G4 Platinum CGM system experienced significant A1C reduction and spent more time in target range compared to a control group that used a standard meter to test glucose.
“This study represents a significant step forward for the diabetes community,” lead study investigator Dr. Roy Beck said in prepared remarks. “The results allow us to confidently tell people with Type 2 diabetes using insulin they can use CGM to take control of their disease and make better treatment decisions.”
The study, which was published today in the Annals of Internal Medicine, demonstrated that after 24 weeks, people with Type II diabetes using CGM while on insulin therapy averaged a 0.8% A1C reduction compared to baseline. The group of participants using CGM also increased time in target range by 1.3 hours compared to baseline and 0.6 hours compared to the control group.
Dexcom noted that the participants in the study experienced significant reductions in A1C, regardless of age or education level.
“We have been successful in driving innovation and adoption of CGM in the Type I diabetes community, but this arm of the DIaMonD study is one of the first to examine how well CGM works for people with Type II diabetes on MDI,” president & CEO Kevin Sayer said. “We are pleased to see a significant A1C reduction in this study, showing that the millions of people globally with Type II diabetes on MDI insulin therapy can benefit from CGM use.”
The company also pointed out that at the end of the study, 93% of patients were still using CGM six or more days per week.
DXCM shares were trading at $77.30 in morning activity today, up +5.8%.
See the best minds in medtech live at DeviceTalks Boston on Oct. 2.
